Trial Profile
International Neurological Study: A Stand Alone Study for Participants of A5175 (A Phase IV, Randomized, Open-Label Evaluation of the Efficacy of Once-Daily Protease Inhibitor and Once-Daily Non-Nucleoside Reverse Transcriptase Inhibitor-Containing Therapy Combination for Initial Treatment of HIV-1 Infected Individuals From Diverse Areas of the World)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Atazanavir (Primary) ; Didanosine (Primary) ; Efavirenz (Primary) ; Emtricitabine (Primary) ; Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Lamivudine/zidovudine (Primary)
- Indications HIV infections; HIV-1 infections
- Focus Pharmacodynamics
- 24 Mar 2017 New trial record